La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Adherium Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Paul Mastoridis

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	8.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Paul Mastoridis

less than a year

Mandato

Dr. Paul Mastoridis is Chief Executive Officer of Adherium Limited from February 2024. Paul Mastoridis has many years experience in the pharmaceutical industry, pioneering and leading digital solutions in...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Louis Panaccio	Executive Chairman of the Board	2.5yrs	AU$110.50k	1.01% A$ 115.0k
Daniel Kaplon	Chief Financial Officer	1.8yrs	AU$305.22k	Nessun dato
Paul Mastoridis	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Francis White	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Chris Leigh-Lancaster	VP of Product & Technology	less than a year	Nessun dato	Nessun dato
Cassandra Thomas	Vice President of People and Culture	less than a year	Nessun dato	Nessun dato
Michael Motion	Consultant	3.3yrs	AU$1.14m	Nessun dato
Zoe Park	Head of Software	less than a year	Nessun dato	Nessun dato
Nancy She	Head of Supply Chain and Procurement	less than a year	Nessun dato	Nessun dato
Michael Gormack	Head of Devices	less than a year	Nessun dato	Nessun dato
Emily Austin	Company Secretary	no data	Nessun dato	Nessun dato
John Wilson	Executive Medical Director	7.9yrs	AU$12.71k	Nessun dato

0.6yrs

Durata media

Gestione esperta: Il team dirigenziale di ADR non è considerato esperto (durata media 0.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Louis Panaccio	Executive Chairman of the Board	2.5yrs	AU$110.50k	1.01% A$ 115.0k
Bruce McHarrie	Independent Non-Executive Director	9.1yrs	AU$55.25k	0.049% A$ 5.6k
William Hunter	Independent Non-Executive Director	8.7yrs	AU$50.00k	0.027% A$ 3.1k
Jeremy Curnock-Cook	Independent Non-Executive Director	9.3yrs	AU$50.00k	0.024% A$ 2.7k
George Baran	Non-Executive Director	3.3yrs	AU$50.00k	0.99% A$ 112.5k

8.7yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ADR sono considerati esperti (durata media dell'incarico 8.7 anni).

Adherium Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Adherium Limited, Annual General Meeting, Nov 30, 2023

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Recent updates

Adherium Limited has filed a Follow-on Equity Offering in the amount of AUD 1.57 million.

New minor risk - Shareholder dilution

New major risk - Financial position

New major risk - Market cap size

New major risk - Market cap size

Adherium Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.005 loss in FY 2022)

New major risk - Financial position

New minor risk - Financial data availability

New major risk - Revenue size

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Limited Commences Production and Market Release of the New, Next Generation Ellipta Sensor

Adherium Limited Receives Australian Therapeutic Goods Administration Approval for Next Generation Sensors

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited Receives U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.017 loss in FY 2021)

Adherium Limited Submits FDA 510(K) Application for Next Generation Hailie Sensor for Teva MDI Inhalers

Adherium Limited Submits US FDA Application for Hailie for GSK pMDI inhalers

Adherium Limited Receives U.S. Food and Drug Administration Clearance for Hailie for Ellipta

Adherium Limited Announces Conclusion of Robert Spurr's Assignment as Interim CFO

Adherium Limited Releases Next Gen Platform Integration Services

Adherium Limited Submits US FDA 510(k) Application for Ellipta Inhaler Users to Connect to Hailie Platform with Physiological Parameters

Adherium Limited Announces Board Changes

Adherium Limited Announces That Manufacturing Started for Hailie® for Symbicort® Sensors with Physiological Parameters

Adherium Submits US FDS 510(k) Application for Next Generation Hailie Sensor with Physiological Measures

Adherium Limited announced that it expects to receive AUD 3 million in funding from Trudell Medical Limited, Bioscience Managers Pty Ltd

Independent Non-Executive Director has left the company

Adherium Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.036 loss per share

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media